

The American Psychiatric Association Publishing

TEXTBOOK OF

# **SUBSTANCE USE DISORDER TREATMENT**

SIXTH EDITION

EDITED BY

**Kathleen T. Brady, M.D., Ph.D.  
Frances R. Levin, M.D.  
Marc Galanter, M.D.  
Herbert D. Kleber, M.D.**

AMERICAN  
PSYCHIATRIC  
ASSOCIATION  
PUBLISHING



# **Contents**

Contributors . . . . .	xv
------------------------	----

## **PART I**

### **The Basis of Substance-Related and Addictive Disorders**

<b>1</b> Neurocircuitry of Addiction . . . . .	3
<i>George F. Koob, Ph.D.</i>	
<i>Nora D. Volkow, M.D.</i>	
<b>2</b> Genetics and Epigenetics of Addiction . . . . .	19
<i>Joel Gelernter, M.D.</i>	
<i>Renato Polimanti, Ph.D.</i>	
<b>3</b> Epidemiology of Addiction . . . . .	33
<i>Nathan D.L. Smith, A.L.M.</i>	
<i>Linda B. Cottler, Ph.D., M.P.H., FACE</i>	
<b>4</b> Substance Use Disorder Diagnoses in DSM-5 . . . . .	47
<i>Deborah S. Hasin, Ph.D.</i>	
<i>Farren R.R. Larson, M.A.</i>	

## **PART II**

### **Assessment and Treatment**

<b>5</b> Assessment . . . . .	63
<i>Timothy Fong, M.D.</i>	
<b>6</b> Screening and Brief Intervention . . . . .	77
<i>Richard Saitz, M.D., M.P.H., FACP, DFASAM</i>	

- 21** Neurobiology and Treatment of Anabolic-Androgenic Steroid-Related Disorders . . . . . 315

*Harrison G. Pope Jr., M.D.*

*Gen Kanayama, M.D., Ph.D.*

**PART IV**  
**Nonpharmacotherapeutic**  
**Treatment Modalities**

- 22** Psychodynamic Psychotherapy . . . . . 335

*Edward J. Khantzian, M.D.*

- 23** Cognitive-Behavioral Therapy . . . . . 345

*Kathleen M. Carroll, Ph.D.*

*Brian D. Kiluk, Ph.D.*

- 24** Contingency Management . . . . . 363

*Maxine L. Stitzer, Ph.D.*

*Mary M. Sweeney, Ph.D.*

*Nancy Petry, Ph.D.*

- 25** Motivational Enhancement . . . . . 379

*Matisyahu Shulman, M.D.*

*Katherine Pruzan, Psy.D.*

*Kenneth M. Carpenter, Ph.D.*

- 26** Alcoholics Anonymous and Twelve-Step Facilitation . . . . . 395

*Richard K. Ries, M.D.*

- 27** Family Therapy . . . . . 409

*Peter Steinglass, M.D.*

- 28** Network Therapy . . . . . 423

*Marc Galanter, M.D.*

**29** Digitally Delivered Therapies . . . . . 435

*Sarah E. Lord, Ph.D.*

*Katherine M. Seavey, B.A.*

*Alan J. Budney, Ph.D.*

*Lisa A. Marsch, Ph.D.*

**30** Mindfulness, Exercise, and Other Alternative Therapies . . . . . 449

*Sarah Bowen, Ph.D.*

*Adam D. Wilson, M.S.*

*Cameron S. Laue, B.A.*

**PART V**  
**Public Health Issues**

**31** The U.S. Opioid Crisis . . . . . 463

*Wilson M. Compton, M.D., M.P.E.*

*Christopher M. Jones, Pharm.D., Dr.P.H.*

**32** Cannabis Policy and Use . . . . . 481

*Arthur Robin Williams, M.D., M.B.E.*

**33** HIV/AIDS and Hepatitis C Virus . . . . . 495

*Andrea Norcini Pala, Ph.D.*

*Robert H. Remien, Ph.D.*

**34** Nicotine and Public Health . . . . . 505

*K. Michael Cummings, Ph.D., M.P.H.*

*Ron Borland, Ph.D., FASSA*

*David Braak, M.D. candidate*

**35** Prevention of Substance Use Disorders . . . . . 527

*Katrina E. Champion, Ph.D.*

*Nicola C. Newton, Ph.D.*

*Maree Teesson, Ph.D.*

**PART VI**  
**Special Populations**

<b>36</b>	Substance-Related Disorders in Women . . . . .	541
	<i>Grace Hennessy, M.D.</i>	
	<i>Constance Guille, M.D.</i>	
	<i>Shelly F. Greenfield, M.D., M.P.H.</i>	
<b>37</b>	Substance-Related Disorders in Adolescents . . .	563
	<i>Amanda T. Roten, M.D.</i>	
	<i>Kevin M. Gray, M.D.</i>	
<b>38</b>	Substance-Related Disorders in Patients With Chronic Pain. . . . .	575
	<i>Kelly S. Barth, D.O.</i>	
	<i>Allison J. Smith, M.D.</i>	
<b>39</b>	Substance Use and Related Disorders in Sexual and Gender Minority Populations . . . .	591
	<i>Jeremy D. Kidd, M.D., M.P.H.</i>	
<b>40</b>	Cross-Cultural Aspects of Substance-Related and Addictive Disorders . . . . .	609
	<i>Nady el-Guebaly, M.D., D.Psych., D.P.H.</i>	
	<i>Hyoun S. Kim, M.A.</i>	
<b>41</b>	Substance-Related Disorders in Older Adults . . .	629
	<i>Maria A. Sullivan, M.D., Ph.D.</i>	
<b>42</b>	Behavioral Addictive Disorders . . . . .	651
	<i>Mayumi Okuda, M.D.</i>	
	<i>Maria Alejandra Gallo Ruiz, M.D.</i>	
	<i>Matisyahu Shulman, M.D.</i>	

**PART VII**  
**Psychiatric Comorbidity**  
**in Substance-Related Disorders**

<b>43</b>	Epidemiology of Co-Occurring Psychiatric and Substance Use Disorders . . . . .	667
	<i>Jeffrey D. Schulden, M.D.</i>	
	<i>Carlos Blanco, M.D., Ph.D., M.S.</i>	
<b>44</b>	Mood Disorders . . . . .	681
	<i>Jonathan M. Wai, M.D.</i>	
	<i>Matisyahu Shulman, M.D.</i>	
	<i>Edward Nunes, M.D.</i>	
<b>45</b>	Anxiety Disorders . . . . .	701
	<i>Kathleen T. Brady, M.D., Ph.D.</i>	
	<i>Sudie E. Back, Ph.D.</i>	
<b>46</b>	Eating Disorders . . . . .	715
	<i>Therese K. Killeen, Ph.D., A.P.R.N.</i>	
	<i>Timothy D. Brewerton, M.D.</i>	
<b>47</b>	Attention-Deficit/Hyperactivity Disorder . . . . .	731
	<i>Timothy E. Wilens, M.D.</i>	
	<i>Tamar A. Kaminski, B.S.</i>	
<b>48</b>	Trauma- and Stressor-Related Disorders . . . . .	745
	<i>Skye Fitzpatrick, Ph.D.</i>	
	<i>Amber Jarnecke, Ph.D.</i>	
	<i>Sudie Back, Ph.D.</i>	
	<i>Elizabeth Straus, Ph.D.</i>	
	<i>Sonya Norman, Ph.D.</i>	
	<i>Denise A. Hien, Ph.D.</i>	

<b>49</b>	Schizophrenia Spectrum and Other Psychotic Disorders . . . . .	759
	<i>Elizabeth K.C. Schwartz, M.D., Ph.D.</i>	
	<i>Mary F. Brunette, M.D.</i>	
	<i>Alan I. Green, M.D.</i>	
PART V		
Special Topics		
<b>50</b>	Testing for Substances of Abuse . . . . .	775
	<i>David A. Gorelick, M.D., Ph.D., DLFAPA, FASAM</i>	
<b>51</b>	Forensic Addiction Psychiatry . . . . .	791
	<i>Elie G. Aoun, M.D.</i>	
	<i>Jungjin Kim, M.D.</i>	
<b>52</b>	Medical Education on Addiction . . . . .	807
	<i>Jeffrey J. DeVido, M.D., M.T.S., FASAM</i>	
	<i>Ellen L. Edens, M.D., M.P.E., M.A.</i>	
	<i>Robert Werner, M.D.</i>	
	<i>Elizabeth F. Howell, M.D., M.S., DLFAPA, DFASAM</i>	
<b>53</b>	Addiction in the Workplace . . . . .	837
	<i>Laurence M. Westreich, M.D.</i>	
	Index . . . . .	849